If you have been reading about REV-ERB agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-17. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
=== N05AA Phenothiazines with aliphatic side-chain === N05AA01 Chlorpromazine N05AA02 Levomepromazine N05AA03 Promazine N05AA04 Acepromazine N05AA05 Triflupromazine N05AA06 Cyamemazine N05AA07 Chlorproethazine
He reprised his role as Kenobi in the 2022 miniseries Obi-Wan Kenobi, and won a Primetime Emmy Award for Outstanding Lead Actor for his portrayal of fashion designer Halston in the miniseries Halston (2021). McGregor also appeared in the motorcycle-travel documentary series Long Way Round, Long Way Down, Long Way Up, and Long Way Home alongside Charley Boorman. He starred in theatre productions of Guys and Dolls (2005–2007) and Othello (2007–2008). McGregor has been involved in charity work and has served as an ambassador for UNICEF UK since 2004.
Mental illness is often discussed on social media and several studies have noted a link between it and severe psychiatric disorders. Studies such as one in 1998 led by Robert E. Kraut indicated that Internet can have an impact on a person's daily life and that increased amounts of time online can have a detrimental impact on interpersonal relationships and social interactions, which can in turn lead to increased depression and alienation. Today, social media platforms such as Twitter or Instagram have increased the amount of personal interaction with other users. There is current research that explores the role social media has in assisting people find resources and networks to support one's mental health. The interconnectivity between users through social media has encouraged many to seek help with professionals while also reducing the stigma surrounding mental illnesses. Though these claims are still being researched, there is a notable rise in communication within social media as a whole. The Scottish Health Survey conducted a study monitoring screen time and mental health in individuals. The research concluded that adults ages 16–99 who watch TV more than three hours a day were more likely to have poor mental health. 3 hours or more of television or screen time in children lead to a downward trend in mental health positivity. The study concluded that there is a correlation between screen time and a decline in mental health.
Sources: en.wikipedia.org
=== Genes addition, deletion and modification === Recombinant SeV variants has been constructed by introducing new genes and/or by deleting some viral genes such as F, M, and HN from the SeV genome. Reporter genes, such as those that are coding luciferase, green or red fluorescent proteins can be inserted in different locations in the viral genome. These locations include positions upstream of the N gene, between the N and P genes, between P and M, M and F, F and HN, HN and L, and after the L gene. SeV constructs have also been created with a modified protease cleavage site in fusion protein (F). The SeV F protein is a type I membrane glycoprotein that is synthesized as an inactive precursor (F0) that must be activated by proteolytic cleavage at residue arginine-116. After the cleavage F0 precursor yields two disulfide-linked subunits F1 and F2. The proteolytic cleavage site can be changed, so other host proteases would be capable to process F0. Sendai virus based vector system that can deliver CRISPR/Cas9 for efficient gene editing was created.
The hats of the Australian Light Horse are decorated with emu feather plumes. Trademarks of early Australian companies using the emu included Webbenderfer Bros frame mouldings (1891), Mac Robertson Chocolate and Cocoa (1893), Dyason and Son Emu Brand Cordial Sauce (1894), James Allard Pottery Wares (1906), and rope manufacturers G. Kinnear and Sons Pty. Ltd. still use it on some of their products. There are around six hundred gazetted places in Australia with "emu" in their title, including mountains, lakes, hills, plains, creeks and waterholes. During the 19th and 20th centuries, many Australian companies and household products were named after the bird. In Western Australia, Emu beer has been produced since the early 20th century and the Swan Brewery continues to produce a range of beers branded as "Emu". The quarterly peer-reviewed journal of the Royal Australasian Ornithologists Union, also known as Birds Australia, is entitled Emu: Austral Ornithology. The comedian Rod Hull featured a wayward emu puppet in his act for many years and the bird returned to the small screen in the hands of his son Toby after the puppeteer's death in 1999. In 2019, American insurance company Liberty Mutual launched an advertising campaign that features LiMu Emu, a CGI-rendered emu. The animal sanctuary, Alveus Sanctuary, has an emu named Stompy. He was their first animal ambassador, after being hand raised by the Sanctuary's founder. He is known for "giving hugs" to guests at Alveus, including Ludwig, Jaiden Animations, Jack Manifold, Hasan Piker, and Valkryae.
== History == Carbetocin was synthesized before 1971 at the Czechoslovak Institute of Organic Chemistry and Biochemistry and was first described by 1974. It was approved for medical use in Canada and the United Kingdom in 1997.
=== Extraterrestrial pathogens === Hoyle and Wickramasinghe have advanced the argument that various outbreaks of illnesses on Earth are of extraterrestrial origins, including the 1918 flu pandemic and certain outbreaks of polio and mad cow disease. For the 1918 flu pandemic they hypothesised that cometary dust brought the virus to Earth simultaneously at multiple locations—a view almost universally dismissed by external experts on this pandemic. On 24 May 2003 The Lancet published a letter from Wickramasinghe, jointly signed by Milton Wainwright and Jayant Narlikar, in which they hypothesised that the virus that causes severe acute respiratory syndrome (SARS) could be extraterrestrial in origin instead of originating from chickens. The Lancet subsequently published three responses to this letter, showing that the hypothesis was not evidence-based, and casting doubts on the quality of the experiments referenced by Wickramasinghe in his letter. Claims connecting terrestrial disease and extraterrestrial pathogens have been rejected by the scientific community. In 2020, Wickramasinghe and colleagues published a paper claiming that Severe acute respiratory syndrome coronavirus 2, the virus responsible for the COVID-19 pandemic was also of extraterrestrial origin, the claim was criticised for lacking evidence.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.